Brazil's health regulatory agency, Anvisa, seized a counterfeit batch of the drug Mounjaro and recalled other medications this month [1].
These actions aim to protect public health by removing dangerous or mislabeled pharmaceuticals from the supply chain. The seizure of counterfeit weight-loss and diabetes medications highlights a growing global trend of fraudulent pharmacy products targeting high-demand treatments.
Anvisa coordinated the operations to address two distinct issues: intentional falsification and logistical errors. The agency seized one batch of Mounjaro [1], a medication used for type 2 diabetes and weight management, after detecting it was counterfeit [2].
In addition to the counterfeit seizure, Anvisa ordered the recall of specific medications used to treat cholesterol and corticosteroids [1]. These recalls were triggered by the discovery of swapped packaging, a mistake where the wrong medication is placed inside a labeled box [1].
Regulators identified the counterfeit activity and packaging errors on Wednesday, Aug. 7 [1]. The agency said it is working to ensure that these products do not reach patients or are removed from pharmacy shelves immediately [2].
Patients are advised to verify their medication batches and consult healthcare providers if they suspect their medicine is counterfeit or mislabeled [1]. The agency said it continues to monitor distribution channels to prevent further infiltration of fake pharmaceuticals into the Brazilian market [2].
“Anvisa seized one batch of Mounjaro after detecting it was counterfeit.”
The seizure of counterfeit Mounjaro reflects the high risk associated with 'blockbuster' metabolic drugs, which often see a surge in black-market replicas due to high demand and cost. Meanwhile, the recall of cholesterol and corticosteroid drugs due to packaging swaps indicates a failure in quality control at the manufacturing or distribution level, which can lead to critical medication errors for patients.
